Northern Biologics Inc. announced on 8/1/18 the appointment of Enda Moran, Ph.D., MBA, as vice president and head of Chemistry Manufacturing and Controls (CMC), and Frédéric Sweeney, Ph.D., as chief business officer.
“Northern Biologics has recently made an important transition into a clinical-stage immuno-oncology company. In addition to a promising lead candidate, MSC-1, in Phase I clinical development and a rich preclinical pipeline, the quality of the team is essential to the success of our organization,” said Philip Vickers, Ph.D., CEO of Northern Biologics. “Comprehensive and high-quality CMC packages are one key to our future success, as is implementing an effective external partnering strategy. The addition of Enda and Frédéric to the team will ensure rigorous approaches in both of these important areas. On behalf of the entire company and its shareholders, I welcome Enda and Frédéric to the Northern Biologics team and I look forward to working closely with them at this pivotal stage of our development.”
Prior to joining Northern Biologics, Dr. Moran held the position of head of manufacturing sciences at Pfizer. He has extensive experience leading biologics and vaccine programs through the clinical development phases to commercialization, and managing lifecycle changes for commercial products. He previously held technical leadership positions at both Wyeth BioPharma and GlaxoSmithKline. He is an inventor on a number of bioprocess-related patents and has authored numerous peer-reviewed publications in the fields of bioprocessing and biotechnology.
Dr. Moran obtained his Ph.D. in biochemical engineering at the University of Wales, UK, and his MBA at IE Business School in Madrid, Spain.
Dr. Sweeney’s career spans academic research, private and corporate venture capital as well as operations in small and large companies. Most recently, he was vice president of corporate development and head of strategic financing at bioMérieux, a world leader in in vitro diagnostics. Dr. Sweeney had global responsibilities for new technology search and evaluation and for bioMérieux’s strategic investments.
Prior to bioMérieux, he was head of business development and strategy at T2 Biosystems, a venture-backed company in the sepsis diagnostics space. As part of his role at T2 Biosystems, Dr. Sweeney was involved in private capital raises, establishing key strategic partnerships and the initial public offering of TTOO on NASDAQ. Dr. Sweeney obtained his BSc in Biochemistry at McGill University and then completed a Ph.D. focused on DNA repair, signal transduction and structural biology as a Terry Fox Scholar at the University of Toronto.
In November of 2017 Northern named ex Shire R&D chief, Phil Vickers CEO. The company has gained notice for its immuno-oncology pipeline. Its lead candidate, MSC-1, is a first-in-class antibody that targets leukemia inhibitory factor (LIF). MSC-1 is in Ph 1 trials.
